At today's earnings conference of Zhejiang Jingxin Pharmaceutical, company executives stated that the plan to admit Daxiseni to 300 hospitals this year has entered more than 230 hospitals, and the overall hospitalization rate is in line with the company's expectations. Daxiseni's monthly sales in some representative hospitals have exceeded 1,000 boxes. The sales plan for this year is expected to exceed 40 million yuan, and next year it hopes to double on this basis. Xioacai Note: Daxiseni capsules, the first Class 1 new drug of Jingxin Pharmaceutical, which is suitable for short-term treatment of insomnia patients, was approved for listing in December 2023 and was put on sale at the end of March 2024. (Caixin reporter He Fan)
京新药业：地达西尼入院节奏符合预期 今年计划销售超4000万元
Zhejiang Jingxin Pharmaceutical: The rhythm of Daxiseni's hospitalization is in line with expectations. This year's sales plan is expected to exceed 40 million yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.